Juno Therapeutics, Inc. (NASDAQ:JUNO) EVP Robert Azelby sold 12,850 shares of the business’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $44.95, for a total transaction of $577,607.50. Following the sale, the executive vice president now directly owns 37,439 shares in the company, valued at $1,682,883.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Robert Azelby also recently made the following trade(s):
- On Tuesday, August 29th, Robert Azelby sold 12,869 shares of Juno Therapeutics stock. The shares were sold at an average price of $39.95, for a total transaction of $514,116.55.
Juno Therapeutics, Inc. (NASDAQ:JUNO) opened at 44.30 on Friday. Juno Therapeutics, Inc. has a 12 month low of $17.52 and a 12 month high of $47.00. The firm’s market cap is $4.65 billion. The firm has a 50 day moving average of $34.04 and a 200-day moving average of $27.13.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The business had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. During the same period in the previous year, the business posted ($0.64) earnings per share. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. On average, equities research analysts forecast that Juno Therapeutics, Inc. will post ($3.12) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://transcriptdaily.com/2017/09/17/insider-selling-juno-therapeutics-inc-juno-evp-sells-577607-50-in-stock.html.
JUNO has been the topic of a number of research analyst reports. BTIG Research raised shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a report on Monday, August 28th. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 28th. Vetr raised shares of Juno Therapeutics to a “buy” rating in a report on Tuesday, May 23rd. Wells Fargo & Company reissued an “outperform” rating and set a $54.00 price objective (up from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Finally, BidaskClub raised shares of Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 27th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $34.88.
Several large investors have recently modified their holdings of JUNO. Teachers Advisors LLC boosted its holdings in shares of Juno Therapeutics by 12.3% in the fourth quarter. Teachers Advisors LLC now owns 60,834 shares of the biopharmaceutical company’s stock valued at $1,147,000 after acquiring an additional 6,643 shares in the last quarter. Nisa Investment Advisors LLC purchased a new stake in shares of Juno Therapeutics in the first quarter valued at about $200,000. Wells Fargo & Company MN boosted its holdings in shares of Juno Therapeutics by 238.4% in the first quarter. Wells Fargo & Company MN now owns 121,392 shares of the biopharmaceutical company’s stock valued at $2,693,000 after acquiring an additional 85,516 shares in the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of Juno Therapeutics by 111.2% in the first quarter. Canada Pension Plan Investment Board now owns 94,400 shares of the biopharmaceutical company’s stock valued at $2,095,000 after acquiring an additional 49,700 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its holdings in shares of Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 3,800 shares in the last quarter. 70.76% of the stock is currently owned by institutional investors and hedge funds.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.